Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120

Virology

Volumn 409, Issue 2, 2011, Pages 163-174

  Kirchherr, Jennifer L ^a   Hamilton, Jennifer ^a   Lu, Xiaozhi ^a   Gnanakaran, S ^b   Muldoon, Mark ^c   Daniels, Marcus ^b   Kasongo, Webster ^d   Chalwe, Victor ^d   Mulenga, Chanda ^d   Mwananyanda, Lawrence ^d   Musonda, Rosemary M ^d   Yuan, Xing ^a   Montefiori, David C ^a   Korber, Bette T ^b,e   Haynes, Barton F ^a   Gao, Feng ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d Tropical Diseases Research Centre Ndola   (Zambia)

^e SANTA FE INSTITUTE   (United States)

Author keywords

Envelope; Genetic variation; HIV 1; Neutralization; Signature

Indexed keywords

GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADULT; AMINO ACID SUBSTITUTION; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; UNINDEXED SEQUENCE; VIRUS LOAD; VIRUS NEUTRALIZATION;

ADULT; AMINO ACID SUBSTITUTION; ANTIBODIES, NEUTRALIZING; CROSS REACTIONS; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78650280214     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.09.031     Document Type: Article

References (63)

1. Bhattacharya T., Daniels M., Heckerman D., Foley B., Frahm N., Kadie C., Carlson J., Yusim K., McMahon B., Gaschen B., Mallal S., Mullins J.I., Nickle D.C., Herbeck J., Rousseau C., Learn G.H., Miura T., Brander C., Walker B., Korber B. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 2007, 315:1583-1586.
2. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78:13232-13252.
3. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., Decker J.M., Wycuff D., Harris L., Hawkins N., Wood B., Nathe C., Richman D., Tomaras G.D., Bibollet-Ruche F., Robinson J.E., Morris L., Shaw G.M., Montefiori D.C., Mascola J.R. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 2008, 82:11651-11668.
4. Bull M.E., Learn G.H., McElhone S., Hitti J., Lockhart D., Holte S., Dragavon J., Coombs R.W., Mullins J.I., Frenkel L.M. Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J. Virol. 2009, 83:6020-6028.
5. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004, 5:233-236.
6. Cham F., Zhang P.F., Heyndrickx L., Bouma P., Zhong P., Katinger H., Robinson J., van der Groen G., Quinnan G.V. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity. Virology 2006, 347:36-51.
7. Chertova E., Bess J.W., Crise B.J., Sowder I.R., Schaden T.M., Hilburn J.M., Hoxie J.A., Benveniste R.E., Lifson J.D., Henderson L.E., Arthur L.O. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 2002, 76:5315-5325.
8. Cordonnier A., Montagnier L., Emerman M. Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature 1989, 340:571-574.
9. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., Allen S., Hunter E. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004, 303:2019-2022.
10. Desrosiers R.C. Prospects for an AIDS vaccine. Nat. Med. 2004, 10:221-223.
11. Dhillon A.K., Donners H., Pantophlet R., Johnson W.E., Decker J.M., Shaw G.M., Lee F.H., Richman D.D., Doms R.W., Vanham G., Burton D.R. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 2007, 81:6548-6562.
12. Diskin R., Marcovecchio P.M., Bjorkman P.J. Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat. Struct. Mol. Biol. 2010, 17:608-613.
13. Fang G., Zhu G., Burger H., Keithly J.S., Weiser B. Minimizing DNA recombination during long RT-PCR. J. Virol. Meth. 1998, 76:139-148.
14. Gao F., Scearce R.M., Alam S.M., Hora B., Xia S., Hohm J.E., Parks R.J., Ogburn D.F., Tomaras G.D., Park E., Lomas W.E., Maino V.C., Fiscus S.A., Cohen M.S., Moody M.A., Hahn B.H., Korber B.T., Liao H.X., Haynes B.F. Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology 2009, 394:91-98.
15. Gnanakaran S., Lang D., Daniels M., Bhattacharya T., Derdeyn C.A., Korber B. Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J. Virol. 2007, 81:4886-4891.
16. Gnanakaran, S., Daniels, M.G., Bhattacharya, T., Lapedes, A.S., Sethi, A., Li, M., Tang, H., Greene, K., Gao, H., Haynes, B.F., Cohen, M.S., Shaw, G.M., Seaman, M.S., Kumar, A., Gao, F., Montefiori, D.C., Korber, B., 2010. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput. Biol. 6, e1000955.
17. Haynes B.F., Montefiori D.C. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccin. 2006, 5:347-363.
18. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20:W13-W23.
19. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310:1025-1028.
20. Huang W., Toma J., Fransen S., Stawiski E., Reeves J.D., Whitcomb J.M., Parkin N., Petropoulos C.J. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J. Virol. 2008, 82:5584-5593.
21. Humphrey W., Dalke A., Schulten K. VMD: visual molecular dynamics. J. Mol. Graph. 1996, 14(33-38):27-38.
22. Irungu J., Go E.P., Zhang Y., Dalpathado D.S., Liao H.X., Haynes B.F., Desaire H. Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein. J. Am. Soc. Mass Spectrom. 2008, 19:1209-1220.
23. Kalia V., Sarkar S., Gupta P., Montelaro R.C. Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41. J. Virol. 2005, 79:2097-2107.
24. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., Wei X., Jiang C., Kirchherr J.L., Gao F., Anderson J.A., Ping L.H., Swanstrom R., Tomaras G.D., Blattner W.A., Goepfert P.A., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Cohen M.S., Montefiori D.C., Haynes B.F., Gaschen B., Athreya G.S., Lee H.Y., Wood N., Seoighe C., Perelson A.S., Bhattacharya T., Korber B.T., Hahn B.H., Shaw G.M. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 2008, 105:7552-7557.
25. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 1980, 16:111-120.
26. Kirchherr J.L., Lu X., Kasongo W., Chalwe V., Mwananyanda L., Musonda R.M., Xia S.M., Scearce R.M., Liao H.X., Montefiori D.C., Haynes B.F., Gao F. High throughput functional analysis of HIV-1 env genes without cloning. J. Virol. Meth. 2007, 143:104-111.
27. Korber B., Gnanakaran S. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr. Opin. HIV AIDS 2009, 4:408-417.
28. Korber B.T., Letvin N.L., Haynes B.F. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J. Virol. 2009, 83:8300-8314.
29. Kulkarni S.S., Lapedes A., Tang H., Gnanakaran S., Daniels M.G., Zhang M., Bhattacharya T., Li M., Polonis V.R., McCutchan F.E., Morris L., Ellenberger D., Butera S.T., Bollinger R.C., Korber B.T., Paranjape R.S., Montefiori D.C. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology 2009, 385:505-520.
30. LaBranche C.C., Sauter M.M., Haggarty B.S., Vance P.J., Romano J., Hart T.K., Bugelski P.J., Marsh M., Hoxie J.A. A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. J. Virol. 1995, 69:5217-5227.
31. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79:10108-10125.
32. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., Decker J.M., Li Y., Salazar M.G., Polonis V.R., Mlisana K., Karim S.A., Hong K., Greene K.M., Bilska M., Zhou J., Allen S., Chomba E., Mulenga J., Vwalika C., Gao F., Zhang M., Korber B.T., Hunter E., Hahn B.H., Montefiori D.C. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 2006, 80:11776-11790.
33. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., Wu X., Shaw G.M., Connors M., Wyatt R.T., Mascola J.R. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 2007, 13:1032-1034.
34. Lin G., Nara P.L. Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr. HIV Res. 2007, 5:514-541.
35. Liu S.L., Rodrigo A.G., Shankarappa R., Learn G.H., Hsu L., Davidov O., Zhao L.P., Mullins J.I. HIV quasispecies and resampling. Science 1996, 273:415-416.
36. Moore J.P., McCutchan F.E., Poon S.W., Mascola J., Liu J., Cao Y., Ho D.D. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J. Virol. 1994, 68:8350-8364.
37. Moore P.L., Gray E.S., Choge I.A., Ranchobe N., Mlisana K., Abdool Karim S.S., Williamson C., Morris L. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 2008, 82:1860-1869.
38. Moore P.L., Ranchobe N., Lambson B.E., Gray E.S., Cave E., Abrahams M.R., Bandawe G., Mlisana K., Abdool Karim S.S., Williamson C., Morris L. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009, 5:e1000598.
39. Morris J.F., Sternberg E.J., Gutshall L., Petteway S.R., Ivanoff L.A. Effect of a single amino acid substitution in the V3 domain of the human immunodeficiency virus type 1: generation of revertant viruses to overcome defects in infectivity in specific cell types. J. Virol. 1994, 68:8380-8385.
40. Palmer S., Kearney M., Maldarelli F., Halvas E.K., Bixby C.J., Bazmi H., Rock D., Falloon J., Davey R.T., Dewar R.L., Metcalf J.A., Hammer S., Mellors J.W., Coffin J.M. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 2005, 43:406-413.
41. R Development Core Team A Language and Environment for Statistical Computing 2009, R Foundation for Statistical Computing, Vienna, Austria.
42. Rademeyer C., Moore P.L., Taylor N., Martin D.P., Choge I.A., Gray E.S., Sheppard H.W., Gray C., Morris L., Williamson C. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology 2007, 368:172-181.
43. Rong R., Gnanakaran S., Decker J.M., Bibollet-Ruche F., Taylor J., Sfakianos J.N., Mokili J.L., Muldoon M., Mulenga J., Allen S., Hahn B.H., Shaw G.M., Blackwell J.L., Korber B.T., Hunter E., Derdeyn C.A. Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J. Virol. 2007, 81:5658-5668.
44. Rong R., Li B., Lynch R.M., Haaland R.E., Murphy M.K., Mulenga J., Allen S.A., Pinter A., Shaw G.M., Hunter E., Robinson J.E., Gnanakaran S., Derdeyn C.A. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 2009, 5:e1000594.
45. Saitou N., Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 1987, 4:406-425.
46. Salazar-Gonzalez J.F., Bailes E., Pham K.T., Salazar M.G., Guffey M.B., Keele B.F., Derdeyn C.A., Farmer P., Hunter E., Allen S., Manigart O., Mulenga J., Anderson J.A., Swanstrom R., Haynes B.F., Athreya G.S., Korber B.T., Sharp P.M., Shaw G.M., Hahn B.H. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 2008, 82:3952-3970.
47. Sather D.N., Armann J., Ching L.K., Mavrantoni A., Sellhorn G., Caldwell Z., Yu X., Wood B., Self S., Kalams S., Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 2009, 83:757-769.
48. Shen X., Parks R.J., Montefiori D.C., Kirchherr J.L., Keele B.F., Decker J.M., Blattner W.A., Gao F., Weinhold K.J., Hicks C.B., Greenberg M.L., Hahn B.H., Shaw G.M., Haynes B.F., Tomaras G.D. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J. Virol. 2009, 83:3617-3625.
49. Shimizu N., Haraguchi Y., Takeuchi Y., Soda Y., Kanbe K., Hoshino H. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein. Virology 1999, 259:324-333.
50. Shimodaira H. Approximately unbiased tests of regions using multistep-multiscale bootstrap resampling. Ann. Stat. 2004, 32:2616-2641.
51. Shioda T., Oka S., Ida S., Nokihara K., Toriyoshi H., Mori S., Takebe Y., Kimura S., Shimada K., Nagai Y., et al. A naturally occurring single basic amino acid substitution in the V3 region of the human immunodeficiency virus type 1 env protein alters the cellular host range and antigenic structure of the virus. J. Virol. 1994, 68:7689-7696.
52. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat. Med. 2009, 15:866-870.
53. Storey J.D., Tibshirani R. Statistical significance for genomewide studies. Proc. Natl Acad. Sci. USA 2003, 100:9440-9445.
54. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22:4673-4680.
55. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas C.F., Burton D.R., Ho D.D., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 1995, 69:6609-6617.
56. Verhofstede C., Demecheleer E., De Cabooter N., Gaillard P., Mwanyumba F., Claeys P., Chohan V., Mandaliya K., Temmerman M., Plum J. Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A. J. Virol. 2003, 77:3050-3057.
57. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Miiro G., Serwanga J., Pozniak A., McPhee D., Manigart O., Mwananyanda L., Karita E., Inwoley A., Jaoko W., Dehovitz J., Bekker L.G., Pitisuttithum P., Paris R., Allen S., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a New HIV-1 vaccine target. Science 2009, 326:285-289.
58. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
59. Wu X., Yang Z.-Y., Li Y., Hogerkorp C.-M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., Longo N.S., McKee K., O'Dell S., Louder M.K., Wycuff D.L., Feng Y., Nason M., Doria-Rose N., Connors M., Kwong P.D., Roederer M., Wyatt R.T., Nabel G.J., Mascola J.R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
60. Zhang P.F., Cham F., Dong M., Choudhary A., Bouma P., Zhang Z., Shao Y., Feng Y.R., Wang L., Mathy N., Voss G., Broder C.C., Quinnan G.V. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc. Natl Acad. Sci. USA 2007, 104:10193-10198.
61. Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., Do Kwon Y., Scheid J., Shi W., Xu L., Yang Y., Zhu J., Nussenzweig M.C., Sodroski J., Shapiro L., Nabel G.J., Mascola J.R., Kwong P.D. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.
62. Zhu P., Chertova E., Bess J., Lifson J.D., Arthur L.O., Liu J., Taylor K.A., Roux K.H. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc. Natl Acad. Sci. USA 2003, 100:15812-15817.
63. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75:10892-10905.